The UK has approved Eli Lilly’s new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline. However, the National Institute for Health and Care Excellence (NICE) determined it is too costly for widespread use within the NHS. This decision comes despite the Medicines and Healthcare products Regulatory Agency (MHRA) deeming the drug safe […]
Lupin said that the UK’ National Institute for Health and Care Excellence (NICE) has recommended Namuscla (mexiletine), an antimyotonic agent, for the approval of its use in the treatment of symptomatic myotonia in adults with non-dystrophic myotonic disorders (NDM). The Indian pharma company, through its subsidiary — Lupin Healthcare (UK), has agreed to a confidential […]
